Abstract
This application claims two crystalline forms and inhaled formulations of a the selective phosphatidylinositol 3-kinase-δ inhibitor (PI3Kδ) inhibitor 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N, N-bis(2-methoxyethyl)hex-5-ynamide. These formulations are claimed to be useful in the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease.
Declaration of interest
The author has received an honorarium from Informa in preparation of this manuscript.